Xeltis has announced encouraging results from a European clinical trial evaluating Xabg, an artificial coronary artery bypass conduit that gradually transitions to living tissue through supramolecular chemistry. Utilizing polymer nanofiber electrospinning, this implant seeks to restore vascular function by being replaced with patients' own healthy tissue. These data support the potential of regenerative biomaterials in cardiovascular surgery and tissue engineering.